Recovery & Repair · Myostatin/activin inhibitor · Compounded 503A
Follistatin-344: myostatin inhibition for lean-mass preservation.
Follistatin is the body's native brake on myostatin — the growth factor that limits how much skeletal muscle you can carry. Follistatin-344 is the 344-amino-acid isoform investigated for muscle preservation in sarcopenia, midlife lean-mass loss, and during rapid weight loss on GLP-1 therapy.
What Follistatin-344 is
Follistatin is a glycoprotein that binds and neutralizes several TGF-β family members — most importantly myostatin (GDF-8) and activin A — both of which act as negative regulators of skeletal muscle mass.
Follistatin-344 (FST-344) is the longer of two major isoforms, with strong tissue-binding properties and a robust ability to sequester circulating myostatin.
It is investigational in the U.S. and used through compounded pharmacy pathways for muscle-preservation indications. Clinical interest has accelerated with the GLP-1 era, where lean-mass loss during rapid weight loss is a documented concern.
How it works
Myostatin is the dominant negative regulator of skeletal muscle growth. Mice and humans with myostatin mutations are visibly hyper-muscled. Follistatin binds myostatin in a 2:1 ratio and neutralizes its receptor binding — releasing the brake on muscle growth.
Activin A — another TGF-β family member — is also bound by follistatin. Activin A drives muscle wasting in cancer cachexia and chronic disease, so follistatin's anti-activin activity contributes to its muscle-preservation effect.
Net result: in tissues exposed to follistatin, skeletal muscle satellite cell proliferation increases and protein degradation falls — supporting both growth and preservation.
What patients use it for
Lean-mass preservation on GLP-1s
The most clinically relevant modern use case — preserving skeletal muscle during rapid weight loss on semaglutide or tirzepatide, where lean-mass loss can reach 25–40% of total weight lost.
Sarcopenia support
Age-related muscle loss is partly driven by rising activin A and unchecked myostatin signaling. Follistatin directly counters both.
Recovery from disuse atrophy
After surgery, immobilization, or extended illness — when muscle wasting is rapid — follistatin's anti-atrophy mechanism is mechanistically aligned.
Performance and recovery
In athletic populations, satellite cell activation and reduced myostatin tone support training adaptation and recovery.
Evidence summary
McPherron AC et al. (Nature, 1997) demonstrated that myostatin knockout produces dramatic muscle hyperplasia in mice — the foundational paper establishing myostatin as the dominant negative regulator of muscle mass.
Lee SJ (PLOS One, 2007) showed that follistatin overexpression produces quadrupled muscle mass in mice via myostatin and activin inhibition.
Mendell JR et al. (Molecular Therapy, 2015) reported safety and biological activity of AAV1-FS344 (a follistatin gene therapy) in Becker muscular dystrophy patients.
Direct human clinical trial data for injectable follistatin-344 is limited. Honest framing: foundational mechanism is among the best-established in muscle biology; outcome RCTs are sparse.
Dosing and clinical context
General clinical context only. Kindr Health physicians determine the appropriate dose and protocol for each patient based on history and labs. This is not a prescription or dosing recommendation.
Most commonly subcutaneous injection. Protocols vary widely; short courses (4–6 weeks) timed with active weight loss or training cycles are typical.
Compounded follistatin-344 from licensed 503A pharmacies is the typical U.S. dispensing pathway.
Often paired with adequate protein intake, resistance training, and — when clinically indicated — GLP-1 therapy.
Safety and contraindications
Safety data in humans is limited. Generally well-tolerated in early clinical experience.
Theoretical concerns include effects on tissues that express activin receptors (ovary, hypothalamus, immune cells) — long-term effects are not fully characterized.
Contraindications: pregnancy, active malignancy, known hypersensitivity. Use under physician supervision through a licensed 503A pharmacy.
Who it's typically considered for
- Patients on GLP-1 therapy wanting aggressive lean-mass preservation
- Midlife and post-menopausal adults concerned about sarcopenia
- Patients recovering from extended disuse or post-surgical atrophy
- Adults pairing resistance training with explicit muscle-preservation goals
Frequently asked questions
Is follistatin-344 FDA-approved?
No. Follistatin-344 is investigational; compounded preparations are dispensed by licensed 503A pharmacies under physician prescription for off-label use.
Will follistatin replace the need for training?
No. Resistance training, adequate protein, and recovery are the substrate; follistatin removes the brake. Without the substrate the effect is minimal.
Follistatin-344 vs 5-amino-1MQ for muscle preservation?
Different mechanisms. Follistatin removes the myostatin brake; 5-amino-1MQ preserves the NAD+/methylation environment that supports protein synthesis. They can be complementary.
Can women use follistatin-344?
Yes — in fact, post-menopausal women are among the populations with highest sarcopenia risk and may benefit most. Pregnancy is a contraindication.
How long are typical courses?
Short courses (4–6 weeks) timed with active weight loss or training blocks are typical. Continuous long-term use is uncommon and not well characterized.
Does follistatin-344 increase IGF-1?
No direct effect on IGF-1. Its mechanism is myostatin and activin inhibition — distinct from the GH/IGF-1 axis.
Is follistatin-344 banned in sport?
Yes. WADA prohibits myostatin inhibitors in competitive sport. Patients in competitive testing pools should not use it.
Sources
- McPherron AC et al. Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature (1997). — pubmed.ncbi.nlm.nih.gov/9139826
- Lee SJ. Quadrupling muscle mass in mice by targeting TGF-β signaling pathways. PLOS One (2007). — pubmed.ncbi.nlm.nih.gov/17726537
- Mendell JR et al. A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy. Molecular Therapy (2015). — pubmed.ncbi.nlm.nih.gov/25322757
- Lee SJ, McPherron AC. Regulation of myostatin activity and muscle growth. PNAS (2001). — pubmed.ncbi.nlm.nih.gov/11459935
Considering Follistatin-344?
A Kindr Health physician reviews every longevity intake — peptides are prescribed only when medically indicated based on your history and labs. There is no charge for the initial review.
Start your longevity intake →Related peptides
Medically reviewed by Dr. Ana Lisa Carr, MD, MBA
Board-Certified Family Medicine Physician · Lead Provider / Medical Reviewer
NPI 1689841744 · Last reviewed: May 10, 2026
Last reviewed May 10, 2026. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products. Prescriptions require a clinical evaluation; a Kindr Health physician determines eligibility. Not for use in pregnancy. This page provides educational information and is not medical advice.